AHRQ announces ARRA grant programs
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research and Quality announces two HHS funding opportunities Sept. 25 for comparative effectiveness research supported through the American Recovery and Reinvestment Act of 2009 (1"The Gray Sheet" Aug. 10, 2009). Under the Clinical and Health Outcomes Initiative in Comparative Effectiveness (CHOICE) grants (RO1), AHRQ plans to provide up to a total of $100 million to up to 10 awardees. For the Innovative Adaptation and Dissemination of AHRQ Comparative Effectiveness Research Products (iADAPT) grants (R18), AHRQ plans to distribute $29.5 million among 20 to 25 awardees. The CHOICE program seeks applications for research aimed at generating new knowledge to help inform decision-making in priority areas of clinical care, while the iADAPT program looks for new ways to adapt content and delivery mechanisms of the agency's comparative effectiveness research summary guides, especially for underserved patient and consumer populations. Applications are due Dec. 16
You may also be interested in...
AHRQ, NIH Report To Congress On Comparative Effectiveness Spending Plans
Two Health and Human Services agencies will allocate about $250 million this year in comparative effectiveness research funds from the federal stimulus package; the remainder of the $1.1 billion comparative effectiveness money will be put to use in 2010
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.